Biotechnology

CureVac BV

Google

Conference Minutes

CVAC

NVDA

GOOG

GOOGL

CHWY

NVDL

07788

07388

NVDY

NVDD

NVDX

NVDQ

GGLS

GGLL

Below is Dolphin Research's Trans of the FY26 Q1 earnings call for $Alphabet(GOOGL.US) $Alphabet - C(GOOG.US). For our earnings analysis, please see 'AI Google: No ghost stories, only a bumper harvest'.I. Core highlights recap. 1) Shareholder returns: the BOD announced a 5% increase to the quarterly dividend. 2) Outlook: at spot FX, Q2 consolidated revenue is expected to see an ~1 ppt FX tailwind (vs. 3 ppts in Q1); full-year CapEx guidance was raised to $180-190bn (prior $175-185bn)...

Citigroup

NVIDIA

Alphabet - C

Alphabet

Chewy

GraniteShares 2x Long NVDA Daily ETF

XL2CSOPNVDA

XI2CSOPNVDA

YieldMax NVDA Option Income Strategy ETF

Direxion Daily NVDA Bear 1X ETF

T-Rex 2X Long NVIDIA Daily Target ETF

T-Rex 2X Inverse NVIDIA Daily Target ETF

Direxion Daily Googl Bear 1x Shares

Direxion Daily GOOGL Bull 2X Shares

CITIGROUP INC 6.250 NON CUM SER II PFD WI

GOOGL (Trans): ROIC-Disciplined AI Investment to Stay Ahead

Today’s Key News Recap

03690

83690

HMTD

MPNGY

09992

HPPD

00941

80941

HCMD

600941

INTC

04335

01211

81211

HYDD

002594

BYDDF

BYDDY

0326 | Dolphin Research Focus: 🐬 Macro/Industry 1) Data show U.S. import prices rose 1.3% MoM in Feb, beating the 0.5% consensus and marking the biggest increase since 2022, driven by higher fuel and rising import costs for AI-related semiconductors and computers. The print signals a clear pickup in imported inflation, with signs of a second leg up, and higher import costs are likely to pass through to consumer prices. On the same day, Fed Governor Michael Barr said rates will stay on hold until there is sustained progress toward 2% inflation...

Meta Platforms

MEITUAN

MEITUAN-WR

Meituan HK SDR 5to1

Meituan

POP MART

POP MART HK SDR 20to1

CHINA MOBILE

CHINA MOBILE-R

CN Mobile HK SDR 5to1

China Mobile

Intel

INTEL-T

BYD COMPANY

BYD COMPANY-R

BYD HK SDR 10to1

BYD Company Limited

BYD Company

SpaceX IPO Push: Latest Update; GOOGL Unveils AI Memory-Compression Game-Changer | Daily News Recap

Disney

01913

SBDS

The following are the minutes of the 4Q25FY earnings call for $Disney(DIS.US) compiled by Dolphin Research. For a review of the earnings report, please refer to the article &#34;Disney: Short-term Pressure but Guidance Unchanged, Can Iger Turn the Tide Before Leaving?&#34;1. Review of Core Financial Information1. DTC Net User Growth Rebounds Beyond Expectations: Streaming user growth continued to rebound in the fourth quarter, with Disney+ adding 4 million net new users (bundled packages) and Hulu adding 8.6 million (driven by the resumption of the Charter partnership and global brand expansion), both exceeding market expectations. The growth was mainly driven by high-quality content...

PRADA

Solo Brands

Dayforce

Ashland

Dominion Energy

NextDecade

Ameriprise Financial

PAR Tech

Disney (Minutes): Committed to double-digit percentage growth in earnings next year

Circle

CRCL

HSBA

00005

DEFI

HSBC

01763

APO-A

HSHD

The following are the Minutes of the $Circle (CRCL.US) FY25 Q3 earnings call. For a quick interpretation, you can simply review the Quick Interpretation of the financial report. 1. Financial Core Data Review: (1) Performance Overview: USDC circulation reached $73.7 billion, a year-on-year increase of 108%; on-chain transaction volume was $9.6 trillion, a year-on-year increase of 580%. (2) Profitability: Total revenue and reserve earnings were $740 million, a year-on-year increase of 66%; Adjusted EBITDA was $166 million, a year-on-year increase of 78%. The profit margin reached 57%...

Deutsche Boerse AG

HSBC Holdings Plc

HSBC HOLDINGS

Hashdex Bitcoin Futures ETF

Apollo Global

BlackRock

CIRC

SentinelOne

APOLLO GLOBAL MANAGEMENT INC 6.75% CONV PFD STK SER A

HSBC HK SDR 5to1

Circle (Minutes): The Ecological Network is More Important than Commercialization

BioNTech Completes Acquisition of CureVac to Enhance mRNA Capabilities

BioNTech SE announces acquisition of CureVac's certain rights

CureVac BV released FY2025 9 Months earnings on November 24 (EST), actual revenue USD 65.91 M, actual EPS USD 0.8589

CureVac BV released FY2025 Q3 earnings on November 24 (EST), actual revenue USD 63.49 M (forecast USD 25.1 M), actual EPS USD 1.7591 (forecast USD -0.1798)

CureVac BV released FY2025 Semi-Annual Earnings on August 15 (EST), actual revenue USD 2.408 M, actual EPS USD -0.5632

CureVac BV released FY2025 Q2 earnings on August 15 (EST), actual revenue USD 1.457 M (forecast USD 3.907 M), actual EPS USD -0.3096 (forecast USD -0.2128)

CureVac Announces Q2 2025 Financials and Reaches Agreement with BioNTech

UBS Downgrades CureVac Rating to Neutral

CureVac Annual General Meeting Passes All Proposals and Appoints New Members

Halper Sadeh Investigating Potential Misconduct at CureVac

Jefferies Downgrades CureVac Rating to Hold, Target Price to $5.00

JPMorgan Reiterates CureVac's Rating

CureVac NV Reports Strong 2024 Financials, Expanding mRNA R&D

CureVac BV released FY2025 Q1 earnings on May 20 (EST), actual revenue USD 966.66 K (forecast USD 3.732 M), actual EPS USD -0.2504 (forecast USD -0.2054)

CureVac Reports Q1 Earnings and Unveils R&D Progress

CureVac BV to release FY2025 Q1 earnings on May 19, 2025 (EST), forecast revenue USD 3.784 M, EPS USD -0.2072

CureVac's stock price rises, JMP maintains rating

CureVac BV released FY2024 annual earnings on April 11 (EST), actual revenue USD 575.85 M (forecast USD 573.8 M), actual EPS USD 0.7747 (forecast USD 0.6376)

CureVac BV released FY2024 Q4 earnings on April 11 (EST), actual revenue USD 264.39 M (forecast USD 22.53 M), actual EPS USD 0.7058 (forecast USD -0.1976)

CureVac BV released FY2024 Q3 earnings on April 11 After-Market EST, actual revenue USD 551.48 M (forecast USD 154.45 M), actual EPS USD 1.351 (forecast USD 0.4721)

OPTIMI HEALTH CORP

FLAG SHIP ACQUISITION CORPORATION COM USD0.001 (SUB/RIGHT 31/03/2026)

HCW Biologics

GCL Global

Silexion Therapeutics

BiomX

Micware

MetaVia

EMMIS ACQUISITION CORP. ORD USD0.0001 (S/R 12/09/2030)

HORIZON SPACE ACQUISITION II CORP COM USD0.0001 30/03/2026(SUB/RIGHTS)

LABU

IBBQ

SBIO

Evotec Appoints Dr. Ingrid Müller as Chief Operating Officer | EVO Stock News

StockTitan

Evotec SE

First Trust NYSE Arca Biotech Index Fd

Invesco Biotechnology & Genome ETF

Proshares Ultra Nasdaq Biotech

SPDR S&P Biotech

iShares Biotechnology ETF

Direxion S&P Biotech Bull 3X

Invesco Nasdaq Biotechnology ETF

ALPS Medical Breakthrough

VanEck Biotech ETF

Evotec Appoints Dr. Ingrid Müller as Chief Operating Officer  | EVO Stock News

L6EW

XSER

DJMC

DJSC

The pan-European STOXX Europe 600 Index rose 3.05% amid improved market sentiment following a U.S.-Iran ceasefire. Investors are exploring penny stocks, which represent smaller companies with potential value. This article highlights three European penny stocks: Sinteza, IDL Diagnostics, and Dr. Miele Cosmed Group, each showing financial resilience despite challenges. Sinteza is pre-revenue but has improved its net loss, IDL Diagnostics has reduced losses and formed a joint venture, while Dr. Miele Cosmed Group shows financial stability despite declining profit margins. Investors are encouraged to explore these opportunities in the current market landscape.

Simplywall

Ossiam STOXX Europe 600 Equal Weight NR

Xtrackers STOXX EUROPE 600 OIL & GAS UCITS ETF Capitalisation 1C

iShares EURO STOXX Mid UCITS ETF

First Trust STOXX EUROPE

iShares STOXX Europe 50 UCITS ETF

iShares EURO STOXX Small UCITS ETF

European Penny Stocks To Watch In April 2026

ARKG

Pulse Biosciences has appointed Liane R. Teplitsky as Chief Operating Officer, effective April 8, 2026. Teplitsky has a strong background, having served as the former CEO of Artedrone and held senior roles at Abbott Laboratories and St. Jude Medical. She will also continue as Chairman of the Board of Carvolix. Further details regarding the reason for her appointment and any replacements have not been disclosed.

TradingView

iShares US Pharma

Health Care Select Sector SPDR

iShares US Medical Devices

Corvus Pharma

iShares Global Healthcare

VG Health

Ark Genomic Revolution ETF

Liane R. Teplitsky named Chief Operating Officer at Pulse Biosciences

Kepler Capital analyst Karel Zoete has maintained a Buy rating on Corbion NV (0QHL) with a price target of €31.00, while the shares closed at €20.50. The analyst has a 0.5% average return and a 56.35% success rate, covering the Consumer Defensive sector. The current consensus on Corbion NV is a Hold, with an average price target of €19.60.

Tip Ranks

Kepler Capital  Keeps Their Buy Rating on Corbion NV (0QHL)

CureVac BV(CVAC.US)

GOOGL (Trans): ROIC-Disciplined AI Investment to Stay Ahead

Evotec Appoints Dr. Ingrid Müller as Chief Operating Officer | EVO Stock News

European Penny Stocks To Watch In April 2026

Liane R. Teplitsky named Chief Operating Officer at Pulse Biosciences

SpaceX IPO Push: Latest Update; GOOGL Unveils AI Memory-Compression Game-Changer | Daily News Recap

Kepler Capital Keeps Their Buy Rating on Corbion NV (0QHL)